Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation

Journal of Lipid Research

Volumn 53, Issue 1, 2012, Pages 168-174

  Aragonès, Gerard ^a   García Heredia, Anabel ^a   Guardiola, Marta ^a   Rull, Anna ^a   Beltrán Debón, Raúl ^a   Marsillach, Judit ^b   Alonso Villaverde, Carlos ^c   Mackness, Bharti ^a   Mackness, Michael ^a   Pedro Botet, Juan ^d   Pardo Reche, Pedro ^a   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HOSPITAL SON LLÀTZER   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

Antioxidants; Atherosclerosis; High density lipoproteins; HIV infection; Oxidative stress; Paraoxonases

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; BETA 2 MICROGLOBULIN; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PARAOXONASE 3; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CD8 LYMPHOCYTE COUNT; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAST PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPOATROPHY; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OXIDATION; PARAOXONASE 3 BLOOD LEVEL; PARAOXONASE 3 GENE; PRIORITY JOURNAL; PROMOTER REGION; VIRUS LOAD;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 84455188821     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P018457     Document Type: Article

References (41)

1. Boyd, M., and P. Reiss. 2006. The long-term consequences of antiretroviral therapy: a review. J. HIV Ther. 11: 26-35.
2. Bergersen, B. M. 2006. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs. 66: 1971-1987. (Pubitemid 44771934)
3. Rose, H., I. Woolley, J. Hoy, A. Dart, B. Bryant, A. Mijch, and D. Sviridov. 2006. HIV infection and high-density lipoprotein: the effect of disease vs. the effect of treatment. Metabolism. 55: 90-95. (Pubitemid 41736252)
4. Alonso-Villaverde, C., T. Segués, B. Coll-Crespo, R. Pérez-Bernalte, A. Rabassa, M. Gomila, S. Parra, M. A. Gozález-Esteban, M. J. Jiménez-Expósito, and L. Masana. 2003. High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. AIDS. 17: 1173-1178. (Pubitemid 36667760)
5. Parra, S., C. Alonso-Villaverde, B. Coll, N. Ferré, J. Marsillach, G. Aragonès, M. Mackness, B. Mackness, L. Masana, J. Joven, et al. 2007. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis. 194: 175-181. (Pubitemid 47464297)
6. Parra, S., J. Marsillach, G. Aragonès, R. Beltrán, M. Montero, B. Coll, B. Mackness, M. Mackness, C. Alonso-Villaverde, J. Joven, et al. 2010. Association of paraoxonase-1 gene haplotypes with the immunologic outcome of and metabolic disturbances and atherosclerosis in HIV-infected patients. J. Infect. Dis. 201: 627-634.
7. Primo-Parmo, S. L., R. C. Sorenson, J. Teiber, and B. N. La Du. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33: 498-507. (Pubitemid 26159866)
8. Rodríguez-Sanabria, F., A. Rull, R. Beltrán-Debón, G. Aragonès, J. Camps, B. Mackness, M. Mackness, and J. Joven. 2010. Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J. Mol. Histol. 41: 379-386.
9. Deakin, S. P., S. Bioletto, M. L. Bochaton-Piallat, and R. W. James. 2011. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic. Biol. Med. 50: 102-109.
10. Ng, C. J., D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 2 76: 44444-44449.
11. Camps, J., J. Marsillach, and J. Joven. 2009. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 46: 83-106.
12. Mackness, B., R. Quarck, W. Verreth, M. Mackness, and P. Holvoet. 2006. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26: 1545-1550. (Pubitemid 44288981)
13. Ng, C. J., S. Y. Hama, N. Bourquard, M. Navab, and S. T. Reddy. 2006. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol. Genet. Metab. 89: 368-373. (Pubitemid 44767734)
14. Shih, D. M., Y. R. Xia, X. P. Wang, S. S. Wang, N. Bourquard, A. M. Fogelman, A. J. Lusis, and S. T. Reddy. 2007. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res. 100: 1200-1207. (Pubitemid 46684133)
15. Ng, C. J., N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2007. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 1368-1374. (Pubitemid 46809427)
16. Yuan, J., A. Devarajan, R. Moya-Castro, M. Zhang, S. Evans, N. Bourquard, P. Dias, C. Lacout, W. Vainchenker, S. T. Reddy, et al. 2010. Putative innate immunity of antiatherogenic paraoxonase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice. J. Stem Cells. 5: 43-48.
17. Camps, J., I. Pujol, F. Ballester, J. Joven, and J. M. Simó. 2011. Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in gram-negative bacteria. Antimicrob. Agents Chemother. 55: 1325-1331.
18. Aragonès, G., M. Guardiola, M. Barreda, J. Marsillach, R. Beltran- Debon, A. Rull, B. Mackness, M. Mackness, J. Joven, J. M. Simó, et al. 2011. Measurement of serum paraoxonase-3 concentration: method evaluation, reference values and influence of genotypes in a population-based study. J. Lipid Res. 52: 1055-1061.
19. Martínez, E., A. Mocroft, M. A. García-Viejo, J. B. Pérez-Cuevas, J. L. Blanco, J. Mallolas, L. Bianchi, I. Conget, J. Blanch, A. Phillips, et al. 2001. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357: 592-598. (Pubitemid 32179612)
20. Alonso-Villaverde, C., B. Coll, S. Parra, M. Montero, N. Calvo, M. Tous, J. Joven, and L. Masana. 2004. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 110: 2204-2209. (Pubitemid 39372502)
21. Ferré, N., J. Camps, J. Fernández-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnés, E. Vilella, M. Tous, and J. Joven. 2003. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 49: 1491-1497. (Pubitemid 37011737)
22. Marsillach, J., B. Mackness, M. Mackness, F. Riu, R. Beltrán, J. Joven, and J. Camps. 2008. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45: 146-157.
23. Savès, M., P. Morlat, G. Chêne, E. Peuchant, I. Pellegrin, F. Bonnet, N. Bernard, D. Lacoste, R. Salamon, and J. Beylot. 2001. Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy. Clin. Immunol. 99: 347-352.
24. Barrett, J. C., B. Fry, J. Maller, and M. J. Daly. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21: 263-265. (Pubitemid 40202029)
25. Zweig, M. H., and G. Campbell. 1993. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39: 561-577. (Pubitemid 23118304)
26. Schwarz, K. B. 1996. Oxidative stress during viral infection: a review. Free Radic. Biol. Med. 21: 641-649. (Pubitemid 26331094)
27. Manda, K. R., A. Banerjee, W. A. Banks, and N. Ercal. 2011. Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic. Biol. Med. 50: 801-810.
28. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46: 1239-1247. (Pubitemid 43109838)
29. Draganov, D. I., P. L. Stetson, C. E. Watson, S. S. Billecke, and B. N. La Du. 2000. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275: 33435-33442.
30. Reddy, S. T., D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21: 542-547. (Pubitemid 32323386)
31. Liu, Y., B. Mackness, and M. Mackness. 2008. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic. Biol. Med. 45: 743-748.
32. Shih, D. M., Y. R. Xia, J. M. Yu, and A. J. Lusis. 2010. Temporal and tissue-specific patterns of Pon3 expression in mouse: in situ hybridization analysis. Adv. Exp. Med. Biol. 660: 73-87.
33. Belteki, G., S. L. Kempster, A. J. Forhead, D. A. Giussani, A. L. Fowden, A. Curley, D. S. Charnock-Jones, and G. C. Smith. 2010. Paraoxonase-3, a putative circulating antioxidant, is systematically up-regulated in late gestation in the fetal rat, sheep, and human. J. Clin. Endocrinol. Metab. 95: 3798-3805.
34. García-Heredia, A., J. Marsillach, G. Aragonès, M. Guardiola, A. Rull, R. Beltrán-Debón, A. Folch, B. Mackness, M. Mackness, J. Pedro-Botet, et al. 2011. Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. Clin. Biochem. 44: 1320-1324.
35. Tohyama, J., J. T. Billheimer, I. V. Fuki, G. H. Rothblat, D. J. Rader, and J. S. Millar. 2009. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis. 204: 418-423.
36. Pereira, S. A., J. R. Batuca, U. Caixas, T. Branco, J. Delgado-Alves, I. Germano, F. Lampreia, and E. C. Monteiro. 2009. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. Br. J. Clin. Pharmacol. 68: 891-897.
37. Aragonès, G., R. Beltrán-Debón, A. Rull, F. Rodríguez-Sanabria, L. Fernández-Sender, J. Camps, J. Joven, and C. Alonso-Villaverde. 2010. Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Clin. Chem. Lab. Med. 48: 1147-1152.
38. Shlay, J. C., S. Sharma, G. Peng, C. L. Gibert, and C. Grunfeld. 2008. Long-term subcutaneous tissue changes among antiretroviral- naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J. Acquir. Immune Defic. Syndr. 48: 53-62. (Pubitemid 351600854)
39. Maskrey, B. H., I. L. Megson, P. D. Whitfield, and A. G. Rossi. 2011. Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 31: 1001-1006.
40. Mackness, M., A. Bouiller, N. Hennuyer, B. Mackness, M. Hall, A. Tailleux, P. Duriez, B. Delfly, P. Durrington, J. C. Fruchart, et al. 2000. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem. Biophys. Res. Commun. 269: 232-236. (Pubitemid 30440282)
41. Huang, R., R. A. Silva, W. G. Jerome, A. Kontush, M. J. Chapman, L. K. Curtiss, T. J. Hodges, and W. S. Davidson. 2011. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18: 416-422.